GlassScriptPhysician profile
Philip W Tally
NPI 1982660049
$2,442.60
in general payments reported to CMS, 2019-2025
15 companies · $46.67 in 2025
The $46.67 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.75 · 2020: $13.87 · 2021: $62.75 · 2022: $396 · 2023: $1,171 · 2024: $683 · 2025: $46.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $566.57 | 2023-2024 | Infinity |
| Alexion Pharmaceuticals, INC. | $298.61 | 2022-2024 | Ultomiris, Soliris |
| Abbvie INC. | $268.68 | 2022-2024 | |
| Eisai INC. | $243.70 | 2023-2024 | |
| Medtronic, INC. | $151.89 | 2021-2023 | O-Arm, Stealthstation S8 Platform, Stealth Autoguide System |
| Genentech USA, INC. | $125.88 | 2023 | Ocrevus |
| Novo Nordisk INC | $124.55 | 2023 | Wegovy |
| Harmony Biosciences LLC | $124.46 | 2023 | Wakix |
| Emd Serono, INC. | $121.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $116.63 | 2023 | Rexulti |
| Biogen, INC. | $88.88 | 2023 | Tysabri |
| Medtronic USA, INC. | $82.62 | 2019-2020 | |
| Stryker Corporation | $65.27 | 2021-2023 | Monterey Al |
| Djo, LLC | $46.67 | 2025 | Cmf |
| Ethicon US, LLC | $16.34 | 2023 | Dermabond Prineo, Stratafix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Tally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.